ANNX Stock: Annexon, Inc. Stock Price, Analysis & Insights
Get live annx stock price $3.75, comprehensive Annexon, Inc. stock analysis, charts, news, and expert forecast. Real-time annx stock data and investment insights.
Loading chart...
Company Overview
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Company Information
- CEO
- Douglas E. Love
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
Contact Information
- Website
- https://www.annexonbio.com
- Address
- 1400 Sierra Point Parkway
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.25)
Business Model & Strategy
Annexon, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Douglas E. Love, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Annexon, Inc. competes in the Biotechnology within the broader Healthcare. With 447.9 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Annexon, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Annexon, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Annexon, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Annexon, Inc.
- ⚠Investors should consider how Annexon, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
447.88M
P/E Ratio
-2.66
Beta
1.25
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 447.88M market capitalization
- Trading Volume: 3.39M shares traded today
- Price Range: 52-week range of $1.28 - $5.66
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Annexon, Inc.
Annexon, Inc. (ANNX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 447.88M, the company represents a significant player in its market. The stock is currently trading at $3.75 with a positivedaily change of 17.03%.
The company's 106 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -2.66, beta of 1.25, and 52-week price range from $1.28 to $5.66when evaluating investment opportunities.
Why Invest in Annexon, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Douglas E. Love
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.